Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBD dose-ranging and open-label adjunct study in autism spectrum disorder
ACTRN12625001088437Phase 2Not yet recruiting
- Sponsor
- NeuroElevate Biosciences
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cannabidiol, melatonin and acetylcysteine in Autism Spectrum Disorder (ASD), sponsored by NeuroElevate Biosciences. Primary endpoint: Change in irritability and aggression at Week 24. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
cannabidiolmelatoninacetylcysteine
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on ACTRN12625001088437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001088437.